Hua Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hua Yang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Lichun Wei
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 710032 Xi’an, Shaanxi, China
3 shared publications - Shigao Huang
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
2 shared publications - Weiwei Li
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 710032 Xi’an, Shaanxi, China
2 shared publications - Yong Zhu
Department of Radiotherapy, Baoji Central Hospital, 721008 Baoji, Shaanxi, China
2 shared publications - Zi Liu
Department of Radiotherapy Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi 710061, P.R. China
2 shared publications An Yang
School of Information Engineering, Hangzhou Vocational and Technical College, Hangzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer
Background: Concurrent chemoradiotherapy (CCRT) is a cornerstone of treatment for locally advanced cervical cancer, although many patients show a poor response. The tumor microenvironment (TME) is a key determinant of therapeutic resistance and prognosis, with the metabolic reprogramming within specific cellular subsets playing a particularly important role. However, the cellular sources of metabolic heterogeneity in cervical cancer and their clinical implications have yet to be firmly established. Methods: An integrated analysis of single-cell RNA sequencing (scRNA-seq) datasets from eight patients cervical cancer, together with bulk RNA sequencing data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, was conducted. Cellular heterogeneity was characterized using the Seurat and Harmony, while metabolic activity was assessed by integrating five algorithms (AUCell, UCell, singscore, ssGSEA, and AddModuleScore). The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was used to construct a prognostic model, which was subsequently validated in external cohorts. The functional role of the key gene FSTL3 was examined through both in vitro and in vivo experiments. Results: scRNA-seq analyses identified 10 major cell types within the cervical cancer TME. Among these, cancer-associated fibroblasts (CAFs) showed the greatest enrichment of ketone body metabolism-related gene signatures. CAFs with high enrichment of these signatures exhibited enhanced cell–cell communication and were associated with activation of the AP-1 transcription factor network. Analysis of these CAFs led to the development of a nine-gene prognostic signature (KLF4, SERPINF1, CD74, PRPS2, ERRFI1, FSTL3, SOD2, JUN, and CXCL3). A risk model based on these genes predicted survival in the TCGA training and validation sets and in independent GEO cohorts (disease-free survival in GSE44001 and overall survival in GSE52903). A nomogram combining the risk score with clinical variables showed improved predictive performance compared with either the risk score or clinical variables alone. Knockdown of FSTL3 suppressed tumor growth and enhanced sensitivity to irradiation and cisplatin in both in vitro and in vivo models, supporting its functional role in cervical cancer progression and treatment response. Conclusion: These analyses identify a CAF population enriched in ketone body metabolism-related gene expression that may be associated with cervical cancer progression. In addition to establishing a prognostic model for further evaluation, this study identifies FSTL3 as a potential therapeutic target that warrants further mechanistic and pharmacological investigation.
- 16 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Open AccessKetone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer
Background: Concurrent chemoradiotherapy (CCRT) is a cornerstone of treatment for locally advanced cervical cancer, although many patients show a poor response. The tumor microenvironment (TME) is a key determinant of therapeutic resistance and prognosis, with the metabolic reprogramming within specific cellular subsets playing a particularly important role. However, the cellular sources of metabolic heterogeneity in cervical cancer and their clinical implications have yet to be firmly established. Methods: An integrated analysis of single-cell RNA sequencing (scRNA-seq) datasets from eight patients cervical cancer, together with bulk RNA sequencing data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, was conducted. Cellular heterogeneity was characterized using the Seurat and Harmony, while metabolic activity was assessed by integrating five algorithms (AUCell, UCell, singscore, ssGSEA, and AddModuleScore). The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was used to construct a prognostic model, which was subsequently validated in external cohorts. The functional role of the key gene FSTL3 was examined through both in vitro and in vivo experiments. Results: scRNA-seq analyses identified 10 major cell types within the cervical cancer TME. Among these, cancer-associated fibroblasts (CAFs) showed the greatest enrichment of ketone body metabolism-related gene signatures. CAFs with high enrichment of these signatures exhibited enhanced cell–cell communication and were associated with activation of the AP-1 transcription factor network. Analysis of these CAFs led to the development of a nine-gene prognostic signature (KLF4, SERPINF1, CD74, PRPS2, ERRFI1, FSTL3, SOD2, JUN, and CXCL3). A risk model based on these genes predicted survival in the TCGA training and validation sets and in independent GEO cohorts (disease-free survival in GSE44001 and overall survival in GSE52903). A nomogram combining the risk score with clinical variables showed improved predictive performance compared with either the risk score or clinical variables alone. Knockdown of FSTL3 suppressed tumor growth and enhanced sensitivity to irradiation and cisplatin in both in vitro and in vivo models, supporting its functional role in cervical cancer progression and treatment response. Conclusion: These analyses identify a CAF population enriched in ketone body metabolism-related gene expression that may be associated with cervical cancer progression. In addition to establishing a prognostic model for further evaluation, this study identifies FSTL3 as a potential therapeutic target that warrants further mechanistic and pharmacological investigation.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (6)
Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study
To evaluate the efficacy and safety of extended-field intensity-modulated radiotherapy (EF-IMRT) combined with concurrent chemotherapy and high-dose-rate (HDR) brachytherapy in locally advanced cervical cancer with positive para-aortic (PALN) or common iliac lymph nodes (CILN). A multicenter prospective study was conducted involving patients diagnosed with biopsy-proven cervical cancer and positive PALN or CILN, enrolled from 11 hospitals in China. All patients were treated with EF-IMRT with concurrent chemotherapy followed by HDR brachytherapy. The primary endpoint was progression-free survival (PFS), with overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and adverse events as secondary endpoints. Between October 2015 and July 2018, 204 patients with cervical cancer were evaluable in this study, with a median follow-up of 68.7 months. The 3-year and 5-year PFS were 68.3% and 64.6%, respectively. OS at 3 and 5 years were 76.4% and 69.5%, respectively. The 5-year LPFS and DMFS were 83.1% and 70.1%, respectively. Notably, patients with positive PALN had significantly lower PFS, OS, LPFS, and DMFS compared to those with negative PALN (p<0.05). Among patients with PALN involvement, those with positive CILN exhibited significantly lower PFS and DMFS compared to those with negative CILN (p<0.05). Acute grade ≥3 gastrointestinal toxicities occurred in 16.7% of patients, and chronic grade ≥3 gastrointestinal toxicities were observed in 3% of patients. This multicenter study demonstrated that EF-IMRT with concurrent chemotherapy was tolerable and effective for cervical cancer, with favorable local control and OS outcomes. Chinese Clinical Trial Registry (ChiCTR) Identifier: 17011347.
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (6)
Open AccessExtended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study
To evaluate the efficacy and safety of extended-field intensity-modulated radiotherapy (EF-IMRT) combined with concurrent chemotherapy and high-dose-rate (HDR) brachytherapy in locally advanced cervical cancer with positive para-aortic (PALN) or common iliac lymph nodes (CILN). A multicenter prospective study was conducted involving patients diagnosed with biopsy-proven cervical cancer and positive PALN or CILN, enrolled from 11 hospitals in China. All patients were treated with EF-IMRT with concurrent chemotherapy followed by HDR brachytherapy. The primary endpoint was progression-free survival (PFS), with overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and adverse events as secondary endpoints. Between October 2015 and July 2018, 204 patients with cervical cancer were evaluable in this study, with a median follow-up of 68.7 months. The 3-year and 5-year PFS were 68.3% and 64.6%, respectively. OS at 3 and 5 years were 76.4% and 69.5%, respectively. The 5-year LPFS and DMFS were 83.1% and 70.1%, respectively. Notably, patients with positive PALN had significantly lower PFS, OS, LPFS, and DMFS compared to those with negative PALN (p<0.05). Among patients with PALN involvement, those with positive CILN exhibited significantly lower PFS and DMFS compared to those with negative CILN (p<0.05). Acute grade ≥3 gastrointestinal toxicities occurred in 16.7% of patients, and chronic grade ≥3 gastrointestinal toxicities were observed in 3% of patients. This multicenter study demonstrated that EF-IMRT with concurrent chemotherapy was tolerable and effective for cervical cancer, with favorable local control and OS outcomes. Chinese Clinical Trial Registry (ChiCTR) Identifier: 17011347.
- Open Access
- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325424
MVT-Net: A novel cervical tumour segmentation using multi-view feature transfer learning
Cervical cancer is one of the most aggressive malignant tumours of the reproductive system, posing a significant global threat to women’s health. Accurately segmenting cervical tumours in MR images remains a challenging task due to the complex characteristics of tumours and the limitations of traditional methods. To address these challenges, this study proposes a novel cervical tumour segmentation model based on multi-view feature transfer learning, named MVT-Net. The model integrates a 2D global axial plane encoder-decoder network and a 3D multi-scale segmentation network as source and target domains, respectively. A transfer learning strategy is employed to extract diverse tumour-related information from multiple perspectives. In addition, a multi-scale residual blocks and a multi-scale residual attention blocks are embedded in the 3D network to effectively capture feature correlations across channels and spatial positions. Experiments on a cervical MR dataset of 160 images show that our proposed MVT-Net outperforms state-of-the-art methods, achieving a DICE score of , an ASD of mm and superior performance in tumour localisation, shape delineation and edge segmentation. Ablation studies further validate the effectiveness of the proposed multi-view feature transfer strategy. These results demonstrate that our proposed MVT-Net represents a significant advance in cervical tumour segmentation, offering improved accuracy and reliability in clinical applications.- 24 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325424
Open AccessMVT-Net: A novel cervical tumour segmentation using multi-view feature transfer learning
Cervical cancer is one of the most aggressive malignant tumours of the reproductive system, posing a significant global threat to women’s health. Accurately segmenting cervical tumours in MR images remains a challenging task due to the complex characteristics of tumours and the limitations of traditional methods. To address these challenges, this study proposes a novel cervical tumour segmentation model based on multi-view feature transfer learning, named MVT-Net. The model integrates a 2D global axial plane encoder-decoder network and a 3D multi-scale segmentation network as source and target domains, respectively. A transfer learning strategy is employed to extract diverse tumour-related information from multiple perspectives. In addition, a multi-scale residual blocks and a multi-scale residual attention blocks are embedded in the 3D network to effectively capture feature correlations across channels and spatial positions. Experiments on a cervical MR dataset of 160 images show that our proposed MVT-Net outperforms state-of-the-art methods, achieving a DICE score of , an ASD of mm and superior performance in tumour localisation, shape delineation and edge segmentation. Ablation studies further validate the effectiveness of the proposed multi-view feature transfer strategy. These results demonstrate that our proposed MVT-Net represents a significant advance in cervical tumour segmentation, offering improved accuracy and reliability in clinical applications. - Open Access
- 17 October 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (6) , 1586-1594
Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients
A platinum-based concurrent chemoradiotherapy (CCRT) is the standard treatment for refractory cervical cancer (CC). However, the recurrence of disease and the occurrence of metastasis remain prevalent. We observed the long-term efficacy and safety of bevacizumab combined with neoadjuvant chemotherapy (NACT) and CCRT in refractory CC. A total of 62 patients with refractory CC were enrolled in this study from January 2016 to December 2019. The NACT regimen included bevacizumab (7.5 mg/kg), docetaxel (75 mg/m2), and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. The CCRT regimen included bevacizumab (7.5 mg/kg) and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. A dose of 45-50 Gy was prescribed for external beam radiotherapy (EBRT), while 30-35 Gy in 4-5 fractions was prescribed for brachytherapy (BT). Among the patients, 21 patients (33.9%) were at stages IIB-IIIB, 8 patients (12.9%) were at stage IIIC1, 19 patients (30.6%) were at stage IIIC2, and 14 patients (22.6%) were at stage IVB. Pelvic, para-aortic, supraclavicular, and inguinal lymph node metastases were discovered in 41 patients (66.1%). The median follow-up was 49.8 months (12.3-82.7 months). The median tumor volumes pre-treatment, after NACT, and before BT were 84.64 ± 53.15 cm3, 1.64 ± 13.15 cm3, and 0 ± 1.5 cm3, respectively. Complete clinical response (cCR) rates after NACT and EBRT were 35.5% and 66.1%, respectively. Four years after the diagnosis, the overall survival (OS) rate was 78.6%, the local region-free survival (LRFS) rate was 91.3%, the disease-free survival (DFS) rate was 70.6%, and the distant metastasis-free survival (DMFS) rate was 81.4%. A total of 29 patients (46.8%) experienced grade 3/4 hematological toxicity, 3 patients (4.8%) experienced grade 3 gastrointestinal toxicities, and none experienced grade 5 adverse events. Bevacizumab combined with NACT and CCRT significantly improved cCR and OS in refractory CC with acceptable toxicity.
- 17 October 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (6) , 1586-1594
Open AccessEfficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients
A platinum-based concurrent chemoradiotherapy (CCRT) is the standard treatment for refractory cervical cancer (CC). However, the recurrence of disease and the occurrence of metastasis remain prevalent. We observed the long-term efficacy and safety of bevacizumab combined with neoadjuvant chemotherapy (NACT) and CCRT in refractory CC. A total of 62 patients with refractory CC were enrolled in this study from January 2016 to December 2019. The NACT regimen included bevacizumab (7.5 mg/kg), docetaxel (75 mg/m2), and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. The CCRT regimen included bevacizumab (7.5 mg/kg) and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. A dose of 45-50 Gy was prescribed for external beam radiotherapy (EBRT), while 30-35 Gy in 4-5 fractions was prescribed for brachytherapy (BT). Among the patients, 21 patients (33.9%) were at stages IIB-IIIB, 8 patients (12.9%) were at stage IIIC1, 19 patients (30.6%) were at stage IIIC2, and 14 patients (22.6%) were at stage IVB. Pelvic, para-aortic, supraclavicular, and inguinal lymph node metastases were discovered in 41 patients (66.1%). The median follow-up was 49.8 months (12.3-82.7 months). The median tumor volumes pre-treatment, after NACT, and before BT were 84.64 ± 53.15 cm3, 1.64 ± 13.15 cm3, and 0 ± 1.5 cm3, respectively. Complete clinical response (cCR) rates after NACT and EBRT were 35.5% and 66.1%, respectively. Four years after the diagnosis, the overall survival (OS) rate was 78.6%, the local region-free survival (LRFS) rate was 91.3%, the disease-free survival (DFS) rate was 70.6%, and the distant metastasis-free survival (DMFS) rate was 81.4%. A total of 29 patients (46.8%) experienced grade 3/4 hematological toxicity, 3 patients (4.8%) experienced grade 3 gastrointestinal toxicities, and none experienced grade 5 adverse events. Bevacizumab combined with NACT and CCRT significantly improved cCR and OS in refractory CC with acceptable toxicity.
- Open Access
- 16 March 2023
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 23 (2) , 310-316
Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer
The standard of care for locally advanced cervical cancer is concurrent chemoradiotherapy, which is associated with significant toxicity, especially hematologic toxicity. To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during radical chemoradiotherapy for cervical cancer, 40 patients receiving prophylaxis from February 2018 to July 2019 were randomly divided into two arms in a 1:1 ratio. Patients in the study arm (N = 21) received PEG-rhG-CSF, while patients in the control arm (N = 19) received short-acting rhG-CSF. The primary endpoint was the incidence of grade 3–4 neutropenia, and the secondary endpoints were the incidence of febrile neutropenia, chemotherapy delay, and radiotherapy interruption. In addition, dynamic changes in absolute neutrophil count during radical chemoradiotherapy and adverse events were compared between the two groups. There were 0 and 4 cycles of grade 3–4 neutropenia in the PEG-rhG-CSF and rhG-CSF groups, respectively. The incidence of neutropenia of all grades was lower in patients on PEG-rhG-CSF than on rhG-CSF [24.05% (19/79) vs. 56.94% (41/72); p < 0.001]. No patient developed neutropenic fever. The lowest values of neutropenia during concurrent chemoradiotherapy cycles were 2.73 ± 1.02 and 1.91 ± 0.79 × 10 9/ml in the PEG-rhG-CSF and rhG-CSF groups, respectively (p < 0.001). In the PEG-rhG-CSF and rhG-CSF groups, 0 and 8 (11.11%) cycles of chemotherapy were delayed due to neutropenia, respectively (p = 0.01). There was no delay of radiotherapy by more than one week in either group. Prophylactic use of PEG-rhG-CSF during chemoradiotherapy for cervical cancer can effectively prevent neutropenia and associated adverse events. PEG-rhG-CSF may be an effective strategy to provide uninterrupted radical chemoradiotherapy for cervical cancer.
- 16 March 2023
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 23 (2) , 310-316
Open AccessEfficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer
The standard of care for locally advanced cervical cancer is concurrent chemoradiotherapy, which is associated with significant toxicity, especially hematologic toxicity. To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during radical chemoradiotherapy for cervical cancer, 40 patients receiving prophylaxis from February 2018 to July 2019 were randomly divided into two arms in a 1:1 ratio. Patients in the study arm (N = 21) received PEG-rhG-CSF, while patients in the control arm (N = 19) received short-acting rhG-CSF. The primary endpoint was the incidence of grade 3–4 neutropenia, and the secondary endpoints were the incidence of febrile neutropenia, chemotherapy delay, and radiotherapy interruption. In addition, dynamic changes in absolute neutrophil count during radical chemoradiotherapy and adverse events were compared between the two groups. There were 0 and 4 cycles of grade 3–4 neutropenia in the PEG-rhG-CSF and rhG-CSF groups, respectively. The incidence of neutropenia of all grades was lower in patients on PEG-rhG-CSF than on rhG-CSF [24.05% (19/79) vs. 56.94% (41/72); p < 0.001]. No patient developed neutropenic fever. The lowest values of neutropenia during concurrent chemoradiotherapy cycles were 2.73 ± 1.02 and 1.91 ± 0.79 × 10 9/ml in the PEG-rhG-CSF and rhG-CSF groups, respectively (p < 0.001). In the PEG-rhG-CSF and rhG-CSF groups, 0 and 8 (11.11%) cycles of chemotherapy were delayed due to neutropenia, respectively (p = 0.01). There was no delay of radiotherapy by more than one week in either group. Prophylactic use of PEG-rhG-CSF during chemoradiotherapy for cervical cancer can effectively prevent neutropenia and associated adverse events. PEG-rhG-CSF may be an effective strategy to provide uninterrupted radical chemoradiotherapy for cervical cancer.
- 1 December 2016
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 13 (12) , 10309-10313
An Empirical Study on the Effect of Tai Chi Exercise on the Physical and Mental Health of the Elderly Based on Network Data
With the development of information technology, network survey has become a new way of data collection. In this paper, we analyze a series of problems in the physical and mental health of the elderly, through the test method, questionnaire survey method and the mathematical statistics method; we investigate the Tai Chi learning beginners from Ganzhou City. Results show that after the experiment, the old people’s body shape changed, the radian change as WHR, scapular skinfold, waist and abdomen skinfold, weight. The main body function changes are heart rate, diastolic blood pressure, vital capacity, systolic blood pressure; degree of body quality changes as reaction time, eyes closed, one leg standing, grip strength, body anteflexion in sitting position. The mental health degree of change as full of energy, rich emotional life, healthy personality, normal development of intelligence, no mental abnormalities, the above indicators are very significant.
- 1 December 2016
- Published by American Scientific Publishers in Journal of Computational and Theoretical Nanoscience
- Vol. 13 (12) , 10309-10313
An Empirical Study on the Effect of Tai Chi Exercise on the Physical and Mental Health of the Elderly Based on Network Data
With the development of information technology, network survey has become a new way of data collection. In this paper, we analyze a series of problems in the physical and mental health of the elderly, through the test method, questionnaire survey method and the mathematical statistics method; we investigate the Tai Chi learning beginners from Ganzhou City. Results show that after the experiment, the old people’s body shape changed, the radian change as WHR, scapular skinfold, waist and abdomen skinfold, weight. The main body function changes are heart rate, diastolic blood pressure, vital capacity, systolic blood pressure; degree of body quality changes as reaction time, eyes closed, one leg standing, grip strength, body anteflexion in sitting position. The mental health degree of change as full of energy, rich emotional life, healthy personality, normal development of intelligence, no mental abnormalities, the above indicators are very significant.
- 18 January 2006
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2, 1458-1461
Joint error resilient and rate control for H.264
- 18 January 2006
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2, 1458-1461
Joint error resilient and rate control for H.264